Read what's happening in Ampersand's Portfolio.
Bioclinica Names Dr. John Hubbard Chief Executive Officer
Ampersand Exits Chantest Investment
ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc.
Ampersand Sells Viracor-IBT to Eurofins for $255 Million
Bioventus Announces U.S. Debut of Feature-Rich New EXOGEN® Device
NDC Launches New Brand Strategy
Bioventus Acquires DUROLANE Assets from Galderma
Merger to Create Leading Provider of Specialty Outsourced Clinical Services
Shaping the Next Generation of Cardiovascular Devices Through Biomedical Textile Engineering